GCP
AVIR icon

GSA Capital Partners’s Atea Pharmaceuticals AVIR Stock Holding History

GSA Capital Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,071
Closed -$77K – 1619
2024
Q1 		$77K Sell
19,071
-130,807
-87% -$512K 0.01% 1508
2023
Q4 		$457K Sell
149,878
-128,408
-46% -$389K 0.04% 856
2023
Q3 		$835K Buy
278,286
+82,208
+42% +$280K 0.07% 500
2023
Q2 		$733K Buy
196,078
+52,908
+37% +$198K 0.07% 494
2023
Q1 		$480K Buy
143,170
+86,250
+152% +$350K 0.05% 743
2022
Q4 		$274K Buy
+56,920
New +$288K 0.03% 995
2022
Q3 		– Sell
-25,080
Closed -$178K – 1505
2022
Q2 		$178K Buy
+25,080
New +$171K 0.03% 1100

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

GSA Capital Partners's AVIR Position: Q2 2024 in Review

GSA Capital Partners sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 19,071 shares — an estimated $77K sold.

GSA Capital Partners first reported a position in AVIR in Q2 2022 and held it in 7 quarters. The position peaked at $835K in Q3 2023. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

  • GSA Capital Partners reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 19,071 Atea Pharmaceuticals shares in Q2 2024, an estimated $77K.
  • GSA Capital Partners first reported a position in Atea Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • GSA Capital Partners's Atea Pharmaceuticals position peaked at $835K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.